INT115367

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 8.16
Pain Relevance 2.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL6, IL6R) extracellular region (IL6, IL6R) aging (IL6)
plasma membrane (IL6R) enzyme binding (IL6R)
IL6 (Homo sapiens)
IL6R (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 404 96.44 Very High Very High Very High
Inflammation 143 95.64 Very High Very High Very High
depression 1 85.56 High High
cytokine 70 83.00 Quite High
Arthritis 258 82.64 Quite High
anakinra 17 71.68 Quite High
Pain 16 70.44 Quite High
methotrexate 289 67.32 Quite High
corticosteroid 32 44.44 Quite Low
antagonist 7 39.64 Quite Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 409 96.44 Very High Very High Very High
Disease 235 96.00 Very High Very High Very High
INFLAMMATION 167 95.64 Very High Very High Very High
Dementia 8 91.44 High High
Adverse Drug Reaction 5 90.20 High High
Exanthema 9 87.12 High High
Fever 29 86.64 High High
Depression 1 85.56 High High
Stress 3 85.00 Quite High
Necrosis 25 83.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, IL-6 may also bind IL-6R in its soluble form.
IL-6 Binding (bind) of IL-6R
1) Confidence 0.07 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.46 Pain Relevance 0.19
GDNF was closely associated with GFR(alpha)-1 in mRNA levels regardless of the pain state, but IL-6 was not associated with IL-6R(alpha).
IL-6 Binding (associated) of IL-6R
2) Confidence 0.06 Published 2003 Journal Intern. Med. Section Body Doc Link 14686749 Disease Relevance 0 Pain Relevance 0
The binding of IL-6R complexed with IL-6 results in homodimerization of gp130 and signal transduction through Janusactivated kinase (JAK)/signal transducers and activators of transcription (STAT) pathways (Heinrich et al 2003).
IL-6 Binding (complexed) of IL-6R
3) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.57 Pain Relevance 0.17
Tocilizumab, previously known as myeloma receptor antibody (MRA), is a humanized, IgG1 IL-6 receptor monoclonal antibody that binds with high affinity to the 80 kDa component of IL-6R.
IL-6 Binding (binds) of IL-6R
4) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.37 Pain Relevance 0.14
Tocilizumab is a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody that inhibits IL-6 binding to IL-6R [4].
IL-6 Binding (binding) of IL-6R
5) Confidence 0.03 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 1.07 Pain Relevance 0.38
One of them is IL-6 receptor (IL-6R), an IL-6-specific binding molecule with a molecular weight of about 80 kD.
IL-6-specific Binding (binding) of IL-6R
6) Confidence 0.02 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 1.14 Pain Relevance 0.15
In addition, IL-6 can form an association with sIL-6R and transmit a signal through gp130.27 Therefore, it is crucial to inhibit both mIL-6R and sIL-6R-mediated signaling to block IL-6 signaling.18 Tocilizumab is developed by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor antibody onto human IgG1.28 Tocilizumab competes for both the membrane-bound (mIL-6R) and soluble (sIL-6R) forms of human IL-6 receptor, effectively blocking IL-6-mediated signal transmission in cells.18
IL-6 Binding (association) of sIL-6R
7) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857613 Disease Relevance 0.68 Pain Relevance 0.12
The blockade of the biological functions of IL-6 may theoretically be available through a blockade of the gp130 receptor by neutralizing IL-6 or by the prevention of the IL-6/IL-6R complex formation.
IL-6 Binding (formation) of IL-6R
8) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 0.37 Pain Relevance 0.23
The blockade of the biological functions of IL-6 may theoretically be available through a blockade of the gp130 receptor by neutralizing IL-6 or by the prevention of the IL-6/IL-6R complex formation.
IL-6 Binding (formation) of IL-6R
9) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 0.37 Pain Relevance 0.23
When binding to IL-6, both soluble and membrane IL-6R connects to gp130 on the membrane whereby the intracellular signal activating the Jak-STAT pathway is mediated.8,9
IL-6 Binding (binding) of IL-6R
10) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 1.13 Pain Relevance 0.21
Furthermore, since it has the capacity to dissociate IL-6/IL-6R complexes that have already formed, it exhibits an extremely effective blocking action on IL-6 signal trans-duction (Figure 2).


IL-6 Binding (complexes) of IL-6R
11) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.51 Pain Relevance 0.15
In cells expressing IL-6R on their cell surface, IL-6 binds to mIL-6R, and by associating with the gp130 protein transmits a signal into the cells.
IL-6 Binding (binds) of mIL-6R
12) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857613 Disease Relevance 0.68 Pain Relevance 0.10
Tocilizumab inhibits the induction of biological activity due to IL-6 in cells that have expressed both membrane-bound IL-6R and gp130 molecules, and also inhibits the induction of biological activity due to IL-6/IL-6R complex formation in cells that express gp130 alone.
IL-6 Binding (formation) of IL-6R
13) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.40 Pain Relevance 0.13
Tocilizumab inhibits the induction of biological activity due to IL-6 in cells that have expressed both membrane-bound IL-6R and gp130 molecules, and also inhibits the induction of biological activity due to IL-6/IL-6R complex formation in cells that express gp130 alone.
IL-6 Binding (formation) of IL-6R
14) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.40 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox